Kedrion Biopharma, Inc. Introduces Albuked(R) to the US Market

Fort Lee, New Jersey, August 15, 2011 - Kedrion Biopharma, a biopharmaceutical company specializing in the development of innovative plasma derivatives, announces the approval of Albuked®, Albumin (Human), a sterile preparation of albumin protein in an aqueous solution administered intravenously is now available for the US market. Human albumin is a protein produced by the liver and performs multiple functions, including the transport of many small molecules in the blood.

Albumin products are used to manage serious and often life-threatening conditions, such as shock and blood loss due to trauma, burns, and surgery.

“This is our third product launch in the United States in less than three months and that is a testament to Kedrion Biopharma team’s enthusiasm, efforts and focus to serve the interests of the patient and clinical communities,” said Paolo Marcucci, CEO of Kedrion. “Our US subsidiary, Kedrion Biopharma, was incorporated as of June 2, 2011. In this short time period Kedrion has become an integral part of the United States market and will continue to be in the future.”

As part of its ongoing expansion in the United States, Kedrion Biopharma will begin distribution of Albuked in August via designated channel partners. For more information please contact your Kedrion representative or call customer service at 1-855-353-7466.

About Albuked

Albuked is produced from pooled-plasma, heat-treated at 60° C for 10 hours and is indicated and used for hypovolemic shock, burn therapy, hypoproteinemia with and without edema, adult respiratory distress syndrome (ARDS), cardiopulmonary bypass surgery, acute liver failure, neonatal hemolytic disease, sequestration of protein rich fluids, erythrocyte re-suspension, acute nephritis and renal dialysis.

Important Safety Information for Albuked

These products are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses via methods like heat treatment at 60° C for 10 hours. Despite these measures, such products can still potentially transmit disease.

Certain patients, eg, those with a history of congestive cardiac failure, renal insufficiency, or stabilized chronic anemia, are at special risk of developing circulatory overload. Albumin is contraindicated in patients with a history of allergic reaction to albumin human products are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses that can cause disease.

Please see accompanying full Prescribing Information for Albuked for complete details or view at www.albuked.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Kedrion Biopharma

Kedrion Biopharma, Inc., Fort Lee, NJ, is a wholly owned subsidiary of Kedrion S.p.A. Kedrion globally develops, manufactures and distributes human plasma derived medicines that improve people’s quality of life. With over 40 years of experience and expertise, the company plays a major role worldwide providing critical therapies in 40 countries. International headquarters are in Italy with a focus on high quality products, relentless commitment to research and development and substantial industrial capacity to ensure continuous supply. Additional information about Kedrion can be found at www.kedrionusa.com.

The Albuked package insert is attached to the press release and can be accessed at www.albuked.com. For all other inquiries please contact Joe Gibbons at 484-459-4952.

Back to news